Cowan Elvia, SVP of Finance and CAO at Vaxcyte Inc ($PCVX), sold shares on the open market three times over the past year for a total of $703 thousand. Her latest sale occurred on March 11, 2026. These transactions rank her 5,724th out of 11,678 insiders by sale value, well below the average of $8.6 million per seller across 6.37 trades. Cowan Elvia recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | S | Common Stock | 1487 | $55.39 | 29,380.0000 | 136,196,512 | 4.82% | 0.00% |
| March 17, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | S | Common Stock | 405 | $56.26 | 28,975.0000 | 136,196,512 | 1.38% | 0.00% |
| March 11, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | M | Stock Option (right to buy) | 2500 | $0.00 | 96,068.0000 | 136,196,512 | 2.54% | 0.00% |
| March 9, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | F | Common Stock | 495 | $59.32 | 30,867.0000 | 136,196,512 | 1.58% | 0.00% |
| March 11, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | M | Common Stock | 2500 | $25.92 | 33,367.0000 | 136,196,512 | 8.10% | 0.00% |
| March 11, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | S | Common Stock | 2500 | $58.59 | 30,867.0000 | 136,196,512 | 7.49% | 0.00% |
| March 2, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | F | Common Stock | 326 | $61.98 | 31,362.0000 | 136,196,512 | 1.03% | 0.00% |
| Feb. 26, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | M | Stock Option (right to buy) | 7716 | $0.00 | 116,423.0000 | 136,196,512 | 6.22% | 0.01% |
| Feb. 26, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | A | Stock Option (right to buy) | 17855 | $0.00 | 116,423.0000 | 136,196,512 | 18.11% | 0.01% |
| Feb. 28, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | F | Common Stock | 243 | $61.98 | 31,688.0000 | 136,196,512 | 0.76% | 0.00% |
| Feb. 26, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | M | Common Stock | 7716 | $25.92 | 31,931.0000 | 136,196,512 | 31.86% | 0.01% |
| Feb. 26, 2026 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, Finance & CAO | A | Common Stock | 10681 | $0.00 | 24,215.0000 | 136,196,512 | 78.92% | 0.01% |
| Dec. 23, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 4907 | $47.90 | 21,250.0000 | 136,196,512 | 18.76% | 0.00% |
| Dec. 23, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | G | Common Stock | 1000 | $0.00 | 13,534.0000 | 136,196,512 | 6.88% | 0.00% |
| Dec. 23, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 6716 | $47.94 | 14,534.0000 | 136,196,512 | 31.60% | 0.00% |
| Sept. 8, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | F | Common Stock | 482 | $32.41 | 26,156.0000 | 121,997,348 | 1.81% | 0.00% |
| Sept. 2, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | F | Common Stock | 325 | $31.56 | 26,638.0000 | 121,997,348 | 1.21% | 0.00% |
| Sept. 2, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | F | Common Stock | 242 | $31.56 | 26,963.0000 | 121,997,348 | 0.89% | 0.00% |
| Sept. 7, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | A | Common Stock | 2810 | $0.00 | 27,205.0000 | 121,997,348 | 11.52% | 0.00% |
| Aug. 29, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | A | Stock Option (right to buy) | 9743 | $0.00 | 9,743.0000 | 121,997,348 | 9999.99% | 0.01% |
| Feb. 28, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | F | Common Stock | 242 | $73.02 | 24,431.0000 | 121,997,348 | 0.98% | 0.00% |
| Feb. 27, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | A | Stock Option (right to buy) | 17961 | $0.00 | 17,961.0000 | 121,997,348 | 9999.99% | 0.01% |
| March 3, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | F | Common Stock | 325 | $72.10 | 24,106.0000 | 121,997,348 | 1.33% | 0.00% |
| Feb. 27, 2025 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | A | Common Stock | 5379 | $0.00 | 24,673.0000 | 121,997,348 | 27.88% | 0.00% |
| Dec. 16, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Stock Option (right to buy) | 7716 | $0.00 | 106,284.0000 | 123,693,461 | 6.77% | 0.01% |
| Dec. 16, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Common Stock | 7716 | $25.92 | 19,294.0000 | 123,693,461 | 66.64% | 0.01% |
| Nov. 7, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | A | Performance Stock Option (right to buy) | 11900 | $0.00 | 11,900.0000 | 123,693,461 | 9999.99% | 0.01% |
| Sept. 3, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Common Stock | 5000 | $25.92 | 17,723.0000 | 97,157,690 | 39.30% | 0.01% |
| Sept. 3, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 5000 | $107.67 | 12,723.0000 | 97,157,690 | 28.21% | 0.01% |
| Sept. 3, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | F | Common Stock | 1145 | $110.15 | 11,578.0000 | 97,157,690 | 9.00% | 0.00% |
| Sept. 3, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Stock Option (right to buy) | 5000 | $0.00 | 114,000.0000 | 97,157,690 | 4.20% | 0.01% |
| July 16, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 5000 | $85.00 | 12,723.0000 | 97,157,690 | 28.21% | 0.01% |
| July 16, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Common Stock | 5000 | $25.92 | 17,723.0000 | 97,157,690 | 39.30% | 0.01% |
| July 16, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Stock Option (right to buy) | 5000 | $0.00 | 119,000.0000 | 97,157,690 | 4.03% | 0.01% |
| July 8, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 5000 | $80.00 | 30,446.0000 | 97,157,690 | 14.11% | 0.01% |
| July 8, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Stock Option (right to buy) | 5000 | $0.00 | 124,000.0000 | 97,157,690 | 3.88% | 0.01% |
| July 8, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Common Stock | 5000 | $25.92 | 30,446.0000 | 97,157,690 | 19.65% | 0.01% |
| March 1, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Stock Option (right to buy) | 11000 | $0.00 | 129,000.0000 | 97,157,690 | 7.86% | 0.01% |
| Feb. 29, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | A | Common Stock | 5400 | $0.00 | 13,158.0000 | 97,157,690 | 69.61% | 0.01% |
| March 1, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | M | Common Stock | 11000 | $25.92 | 24,158.0000 | 97,157,690 | 83.60% | 0.01% |
| March 1, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 2322 | $73.08 | 21,836.0000 | 97,157,690 | 9.61% | 0.00% |
| March 1, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 4455 | $73.69 | 17,381.0000 | 97,157,690 | 20.40% | 0.00% |
| March 1, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | S | Common Stock | 4901 | $74.90 | 12,480.0000 | 97,157,690 | 28.20% | 0.01% |
| March 2, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | F | Common Stock | 324 | $71.55 | 12,156.0000 | 97,157,690 | 2.60% | 0.00% |
| Feb. 29, 2024 | Vaxcyte, Inc. | $PCVX | Cowan Elvia | SVP, FINANCE | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 97,157,690 | 9999.99% | 0.03% |